Telix Agrees US$1.65 Billion Deal for ITM, Pairing Pipeline With Global Isotope Supply

Telix Pharmaceuticals signed a merger agreement to acquire German radiopharmaceutical maker ITM Isotope Technologies Munich for US$1.65 billion upfront, the Australian-American company said in a statement dated September 21, adding that up to US$700 million more could follow on milestones. The headline number gets most of the attention; the structure is the interesting part. Of the upfront consideration, US$1.25 billion comes as 105.8 million new Telix shares priced at US$11.841 — the 30-day trailing VWAP at signing, set off A$16.65 at an AUD/USD rate of 0.71 — issued as Nasdaq-listed American depositary receipts after escrow periods. Telix also assumes about US$302 million of net debt, and a US$96 million management equity rollover plus transaction expenses sits with the sellers. By disclosed ownership math, Telix holders would own about 76.3% of the combined company and ITM holders about 23.7%.

The escrow and lockup terms run up to 15 months, so the dilution from the share consideration does not hit the free float all at once. Still, 105.8 million new shares is a material expansion — derived from the disclosed figures, roughly 31% more shares on issue than Telix currently has in circulation.

The contingent half is tied squarely to ITM-11 (177Lu-edotreotide), the neuroendocrine-tumor treatment at the center of the deal. Up to US$250 million pays out on U.S. Food and Drug Administration approvals — US$100 million for a first gastroenteropancreatic neuroendocrine tumor indication by December 31, 2027, US$100 million for G2-G3 GEP-NETs by December 31, 2030, and US$50 million for lung neuroendocrine tumors by December 31, 2031. A further US$450 million is linked to ITM-11 net global sales in fiscal 2030 above US$150 million. Milestones can be settled in cash or shares at Telix's election.

What Telix is buying is two things at once. ITM's candidate, ITM-11, has completed Phase 3 development in GEP-NETs, with the COMPETE study (NCT03049189) published in The Lancet on July 2, 2026, and a second Phase 3 trial, COMPOSE (NCT04919226), fully enrolled with an interim analysis expected in the first half of 2027. The release references the planned NDA resubmission for ITM-11 without further detail.

The second, and arguably more structural, asset is ITM's isotope operation. Founded in Munich in 2004, ITM describes itself as the only producer of globally scaled commercial-grade lutetium-177, running two GMP facilities and distributing to more than 65 countries. It posted US$273 million in revenue in 2025, is profitable, and grew at a 40% compound annual rate from 2021 to 2025. For Telix — which already sells diagnostics including Illuccix, Gozellix, and Pixclara — owning the supply chain for the most commercially important therapeutic isotope in radiopharma is a genuine moat, not just a pipeline bolt-on.

Telix management estimates unaudited pro forma 2026 revenue and income exceeding US$1.3 billion for the combination, and expects a positive EBITDA contribution from 2027 onward. Chief Executive Christian Behrenbruch framed the deal as consolidation: "This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures." ITM CEO Andrew Cavey said the combination is "uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals." The release pegs the global nuclear medicine market at US$41 billion by 2034, citing MEDraysintell 2025.

The path to closing is not trivial. Telix's board has approved the deal and more than 90% of ITM shareholders have signed on, but Telix needs its own shareholders to vote yes at an extraordinary general meeting expected in November 2026 under ASX listing rules, plus regulatory approvals and customary conditions. The companies expect to close by the end of fiscal 2026; the release does not define a calendar date for the fiscal year-end.

The initial investor verdict leaned negative: shares fell in Monday trading in Sydney, with one report putting the decline at about 6%. The market's question is the standard one for deals like this — whether the supply-chain and pipeline prize justifies the dilution — and the answer gets its first real test at the November shareholder vote. After that, the calendar is defined by milestones: the ITM-11 NDA resubmission, the December 2027 FDA deadline on the first milestone tranche, and the long-dated fiscal 2030 sales target.